Evidence map›Paper›PMID 19906886›Full record

ArticleJournal of neurophysiology2010

Clinically relevant infusion rates of mu-opioid agonist remifentanil cause bradypnea in decerebrate dogs but not via direct effects in the pre-Bötzinger complex region.

Sanda Mustapic, Tomislav Radocaj, Antonio Sanchez, Zoran Dogas, Astrid G Stucke, Francis A Hopp, Eckehard A E Stuth, Edward J Zuperku

Open access · greenAbstract read
In one paragraph

Article in Journal of neurophysiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Neural basis of opioid-induced respiratory depression and its rescue.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Sanda MustapicDepartment of Anesthesiology, Medical College of Wisconsin, Clement J. Zablocki VA Medical Center, 5000 W. National Ave., Milwaukee, WI 53295, USA.
Tomislav Radocaj
Antonio Sanchez
Zoran Dogas
Astrid G Stucke
Francis A Hopp
Eckehard A E Stuth
Edward J Zuperku
Medical College of Wisconsin · USMilwaukee VA Medical Center · USChildren's Hospital of Wisconsin · USUniversity of Split · HR

Funding

VOLATILE ANESTHETICS AND RESPIRATORY NEUROTRANSMISSIONR01GM059234 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI STUTH, ECKEHARD A · 1999 to 2009
$2.0M
Neuropharmacology of Pontine Control of Breathing FrequencyI01BX000721 · VA · CLEMENT J. ZABLOCKI VA MEDICAL CENTER · PI ZUPERKU, EDWARD J · 2011 to 2018
–
BLRD VA I01 BX000721NIGMS NIH HHS GM-59234-06A1
6 · The paper itself

Abstract

Systemic administration of mu-opioids at clinical doses for analgesia typically slows respiratory rate. Mu-opioid receptors (MORs) on pre-Bötzinger Complex (pre-BötC) respiratory neurons, the putative kernel of respiratory rhythmogenesis, are potential targets. The purpose of this study was to determine the contribution of pre-BötC MORs to the bradypnea produced in vivo by intravenous administration of clinically relevant infusion rates of remifentanil (remi), a short-acting, potent mu-opioid analgesic. In decerebrate dogs, multibarrel micropipettes were used to record pre-BötC neuronal activity and to eject the opioid antagonist naloxone (NAL, 0.5 mM), the glutamate agonist D-homocysteic acid (DLH, 20 mM), or the MOR agonist [D-Ala(2), N-Me-Phe(4), gly-ol(5)]-enkephalin (DAMGO, 100 microM). Inspiratory and expiratory durations (T(I) and T(E)) and peak phrenic nerve activity (PPA) were measured from the phrenic neurogram. The pre-BötC was functionally identified by its rate altering response (typically tachypnea) to DLH microinjection. During intravenous remi-induced bradypnea (approximately 60% decrease in central breathing frequency, f(B)), bilateral injections of NAL in the pre-BötC did not change T(I), T(E), f(B), and PPA. Also, NAL picoejected onto single pre-BötC neurons depressed by intravenous remi had no effect on their discharge. In contrast, approximately 60 microg/kg of intravenous NAL rapidly reversed all remi-induced effects. In a separate group of dogs, microinjections of DAMGO in the pre-BötC increased f(B) by 44%, while subsequent intravenous remi infusion more than offset this DAMGO induced tachypnea. These results indicate that mu-opioids at plasma concentrations that cause profound analgesia produce their bradypneic effect via MORs located outside the pre-BötC region.

Indexed as

Action PotentialsAnalgesics, OpioidAnimalsBrain StemDecerebrate StateDogsEnkephalin, Ala(2)-MePhe(4)-Gly(5)-Excitatory Amino Acid AgonistsFemaleFunctional LateralityHomocysteineMaleMicroinjectionsNaloxoneNarcotic AntagonistsNeuronsAnalgesics, OpioidEnkephalin, Ala(2)-MePhe(4)-Gly(5)-Excitatory Amino Acid Agonistshomocysteic acidHomocysteineNaloxoneNarcotic AntagonistsPiperidinesRemifentanil

Identifiers

PMID19906886
PMCPMC2807229
OpenAlexW2052881256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.